Is STAAR Surgical (STAA) overvalued or fairly valued?

MarketChacha shows STAAR Surgical's valuation in context — a forward P/E of about 25.0, a price-to-book of about 3.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is STAAR Surgical's revenue?

STAAR Surgical reported revenue of $239.4M for FY2026, with net profit of $-80.4M, per official filings.

What is the share price of STAAR Surgical (STAA)?

STAAR Surgical last traded at $24.74 (+1.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

STAAR Surgical

STAA · NYSE · Healthcare · United States

$24.74+1.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:29 PM

Snapshot

TickerSTAA

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees921

HeadquartersLake Forest, United States

Market cap$1.2B

P/B3.5

Volume594.37K

Websitewww.staar.com

Filings tracked5

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.8%
Institutions99.2%
Public & other0.0%

271 institutional holders

As reported by Yahoo Finance.

Top holders

Broadwood Capital, Inc.32.38%
Blackrock Inc.13.39%
Yunqi Capital Ltd6.54%
Madison Avenue Partners, LP4.90%
Vanguard Portfolio Management LLC4.27%
State Street Corporation3.68%
Vanguard Capital Management LLC3.40%
Anatole Investment Management Ltd3.22%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 40.2 points over the period — profitability is trending down.

Net margin trend6.6% → -33.6%

Margin has compressed by about 40.2 points over the period — profitability is trending down.

Return on equity-23.4%

Latest ROE of -23.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $83.4M · EPS 0.17

Est. earnings growth -64.2%

Next fiscal year

Rev $361.5M · EPS 0.99

Est. earnings growth +35.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$15.5952-wk range$35.87

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

+1.9%

Fwd P/E

25.0

P/B

3.5

Beta

1.23

Revenue (FY2026)

$239.4M

Net margin

-33.6%

ROE

-23.4%

Revenue CAGR (2y)

-13.8%

EPS (FY2026)

-1.62

Net profit (FY2026)

$-80.4M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about STAA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$239.4M	$-80.4M	-1.62	-33.6%	-23.4%
FY2024	$313.9M	$-20.2M	-0.41	-6.4%	-5.1%
FY2023	$322.4M	$21.3M	0.43	6.6%	5.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$93.5M	$5.2M	0.10	5.6%
2025Q3	$94.7M	$8.9M	0.18	9.4%
2025Q2	$44.3M	$-16.8M	-0.34	-37.9%
2025Q1	$42.6M	$-54.2M	-1.10	-127.3%
2024Q3	$88.6M	$10.0M	0.20	11.3%
2024Q2	$99.0M	$7.4M	0.15	7.5%
2024Q1	$77.4M	$-3.3M	-0.07	-4.3%
2023Q3	$80.3M	$4.8M	0.10	6.0%
2023Q2	$92.3M	$6.1M	0.12	6.6%
2023Q1	$73.5M	$2.7M	0.05	3.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/22/2026material
8-K — Executive/director change
SEC6/9/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/13/2026material
10-Q filing
SEC5/13/2026
8-K — Reg FD disclosure, Exhibits
SEC4/8/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.